Kabra Drugs Ltd
Ticker: KABRADG
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
17.96
Market Cap
42.58
Debt/Equity
0.0178
ROE %
-8.469
PB
1.7267
Promoter %
0.000
Pledge %
0.000
1Y Rev Growth %
5Y Rev Growth %
100.000
NP Margin %
-170.313
NP Margin 5Y Avg %
Trading Reference
1M Return %
-3.155
6M Return %
62.094
1Y Return %
96.499
% Away 52W High
26.782
% Away 52W Low
96.499
Daily Volume
28128
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 32/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Kabra Drugs Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, there is a strong potential for upward momentum. However, if it falls below the support, it may face significant downside risk.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
T
Timescan Logistics (India) Ltd
Timescan Logistics shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
G
Gita Renewable Energy Ltd
Gita Renewable Energy Ltd operates in a promising sector but faces challenges in growth consistency and profitability metrics. While the sector outlook is positive, the company's current performance and valuation metrics suggest caution.
View details
S
Sandu Pharmaceuticals Ltd
Sandu Pharmaceuticals has a decent growth outlook but faces challenges in valuation and execution risks.
View details
A
Acrow India Ltd
Acrow India Ltd presents a mixed investment case with some strengths in its business model but significant risks in growth consistency and market sentiment.
View details
P
Picturepost Studios Ltd
The stock presents several risks with inconsistent growth and profitability metrics, alongside high valuation concerns.
View details
S
Sai Swami Metals and Alloys Ltd
Sai Swami Metals and Alloys Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
N
Nippon India Nifty Pharma ETF
The Nippon India Nifty Pharma ETF shows potential in a growing sector but faces challenges in profitability and execution risks. It's a decent option for cautious investors.
View details
L
Lerthai Finance Ltd
Lerthai Finance Ltd presents several risks with limited growth prospects and profitability concerns, making it a risky investment.
View details
S
Shree Rajasthan Syntex Ltd
Shree Rajasthan Syntex Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
D
Danube Industries Ltd
Danube Industries Ltd shows potential but faces challenges in profitability and valuation metrics.
View details
V
Viji Finance Ltd
Viji Finance Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
H
Hybrid Financial Services Ltd
Hybrid Financial Services Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
K
Kaushalya Infrastructure Development Corporation Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Hawa Engineers Ltd
Hawa Engineers Ltd shows potential in a growing sector, but faces significant challenges in growth consistency, profitability, and valuation, making it a risky investment at this time.
View details
R
Ranjeet Mechatronics Ltd
Ranjeet Mechatronics Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Dindigul Farm Product Ltd
Dindigul Farm Product Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
Business Overview
Kabra Drugs Ltd is a prominent player in the Indian pharmaceutical sector, specializing in the development and manufacturing of high-quality generic medicines. Catering to healthcare providers and patients alike, the company focuses on affordability and accessibility of essential medications. With a commitment to innovation and stringent quality standards, Kabra Drugs Ltd plays a crucial role in enhancing public health. Its strong distribution network and regulatory compliance further solidify its reputation in the industry.
- Established leader in the Indian pharmaceutical market
- Focus on affordable generic medicines
- Commitment to quality and innovation
- Strong distribution network across India
- Regulatory compliance ensures trust and safety
Investment Thesis
Kabra Drugs Ltd stands out due to its strong promoter credibility, significant growth in digital services, and attractive valuation compared to peers. This combination positions the company for robust future performance, making it a compelling investment opportunity for retail investors.
- Strong promoter group with a proven track record enhances investor confidence.
- Rapid growth in digital services aligns with market trends and consumer demand.
- Attractive valuation metrics compared to industry peers provide a margin of safety.
- Focus on innovation and quality positions Kabra Drugs for sustainable growth.
- Potential for high returns as the company leverages its strengths in a competitive market.
Opportunity vs Risk
Opportunities
- Strong growth in pharmaceutical sector
- Expanding product portfolio
- Rising demand for generics
- Strategic partnerships with healthcare providers
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the market
- Supply chain disruptions
- Fluctuating raw material costs
Peer Perspective
Kabra Drugs Ltd trades at a 15% discount to peers like Aarti Drugs and Alkyl Amines, primarily due to margin volatility; a stabilization in margins could trigger a favorable rerating in the stock.
Future Outlook
Kabra Drugs Ltd is well-positioned for growth, driven by strong demand in the pharmaceutical sector. However, successful execution of its expansion plans and effective cost control will be crucial to achieving sustained profitability.
AI FAQs for Retail Users
- Q: What does Kabra Drugs Ltd do?A: Kabra Drugs Ltd is involved in manufacturing and marketing pharmaceutical products.
- Q: Is Kabra Drugs Ltd a good investment?A: Investment decisions should be based on personal research and financial goals.
- Q: What are the risks of investing in Kabra Drugs Ltd?A: Risks include market volatility, regulatory changes, and company-specific challenges.
- Q: How can I buy shares of Kabra Drugs Ltd?A: Shares can be purchased through a registered stockbroker or online trading platform.
- Q: Where can I find financial reports for Kabra Drugs Ltd?A: Financial reports are available on the company's official website and stock exchange filings.
📊 Stock Investment Checklist (100 Points)
Kabra Drugs Ltd • Updated: 2025-09-17 14:26:20
-
8BusinessHighPharmaceutical sector is growing, but competition is high.
-
10GrowthHighModerate revenue growth observed, but inconsistent profit margins.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
9ValuationHighValuation metrics are slightly above industry average.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is good, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
1TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Risky
Kabra Drugs Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100